ASH 2023 | Feasibility and safety of early discharge in ND AML following intensive induction therapy
Rory Shallis
• 11 Dec 2023
Rory Shallis, MD, Yale Cancer Center, New Haven, CT, shares outcomes for patients discharged before absolute neutrophil count (ANC) recovery following intensive induction therapy for newly diagnosed (ND) acute myeloid leukemia (AML). Those who met specific criteria could be safely discharged early without detriment to overall survival (OS), although this came with a slight increase in infection rates. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Bristol Myers Squibb, Curio Science, Servier, Rigel, Gilead Sciences
